

Eoin Flanagan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5583606/publications.pdf>

Version: 2024-02-01

210
papers

9,636
citations

41258

49
h-index

49773

87
g-index

214
all docs

214
docs citations

214
times ranked

5324
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. <i>Annals of Neurology</i> , 2018, 83, 166-177.	2.8	479
2	Glial fibrillary acidic protein immunoglobulin <sc>G</sc> as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. <i>Annals of Neurology</i> , 2017, 81, 298-309.	2.8	366
3	Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. <i>American Journal of Ophthalmology</i> , 2018, 195, 8-15.	1.7	295
4	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. <i>JAMA Neurology</i> , 2018, 75, 1355.	4.5	286
5	Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. <i>Annals of Neurology</i> , 2016, 79, 775-783.	2.8	263
6	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019, 76, 301.	4.5	243
7	Expanded phenotypes and outcomes among 256 <sc>LGI1</sc>/<sc>CASPR</sc>-positive patients. <i>Annals of Neurology</i> , 2017, 82, 79-92.	2.8	242
8	Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 757-768.	0.9	227
9	Short Myelitis Lesions in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders. <i>JAMA Neurology</i> , 2015, 72, 81.	4.5	209
10	The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. <i>Acta Neuropathologica</i> , 2020, 139, 875-892.	3.9	205
11	Paraneoplastic isolated myelopathy. <i>Neurology</i> , 2011, 76, 2089-2095.	1.5	187
12	International multicenter examination of MOG antibody assays. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	3.1	180
13	Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e161.	3.1	163
14	Attitudes of US medical trainees towards neurology education: "Neurophobia" - a global issue. <i>BMC Medical Education</i> , 2010, 10, 49.	1.0	161
15	Autoimmune Dementia: Clinical Course and Predictors of Immunotherapy Response. <i>Mayo Clinic Proceedings</i> , 2010, 85, 881-897.	1.4	158
16	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. <i>Annals of Neurology</i> , 2016, 79, 437-447.	2.8	148
17	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. <i>Neurology</i> , 2020, 95, e111-e120.	1.5	140
18	Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1-year. <i>Journal of Neuroimmunology</i> , 2018, 321, 157-163.	1.1	136

#	ARTICLE	IF	CITATIONS
19	A multicenter comparison of MOG-IgG cell-based assays. <i>Neurology</i> , 2019, 92, e1250-e1255.	1.5	135
20	Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria. <i>JAMA Neurology</i> , 2019, 76, 56.	4.5	134
21	Area postrema syndrome. <i>Neurology</i> , 2018, 91, e1642-e1651.	1.5	129
22	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. <i>JAMA Neurology</i> , 2021, 78, 741.	4.5	124
23	Predictive models in the diagnosis and treatment of autoimmune epilepsy. <i>Epilepsia</i> , 2017, 58, 1181-1189.	2.6	120
24	“Neurophobia” attitudes of medical students and doctors in Ireland to neurological teaching. <i>European Journal of Neurology</i> , 2007, 14, 1109-1112.	1.7	119
25	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
26	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. <i>JAMA Neurology</i> , 2020, 77, 1420.	4.5	109
27	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. <i>Ophthalmology</i> , 2018, 125, 1628-1637.	2.5	108
28	Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 IgG in Patients in the Optic Neuritis Treatment Trial. <i>JAMA Ophthalmology</i> , 2018, 136, 419.	1.4	104
29	Primary intramedullary spinal cord lymphoma. <i>Neurology</i> , 2011, 77, 784-791.	1.5	101
30	Central canal enhancement and the trident sign in spinal cord sarcoidosis. <i>Neurology</i> , 2016, 87, 743-744.	1.5	94
31	Neurologic autoimmunity and immune checkpoint inhibitors. <i>Neurology</i> , 2020, 95, e2442-e2452.	1.5	94
32	Specific pattern of gadolinium enhancement in spondylotic myelopathy. <i>Annals of Neurology</i> , 2014, 76, 54-65.	2.8	89
33	Acute flaccid myelitis: cause, diagnosis, and management. <i>Lancet</i> , The, 2021, 397, 334-346.	6.3	88
34	Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults. <i>JAMA Neurology</i> , 2015, 72, 1304.	4.5	86
35	Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. <i>Neurology</i> , 2018, 90, e103-e110.	1.5	86
36	Clinical spectrum of high-titre GAD65 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 645-654.	0.9	84

#	ARTICLE	IF	CITATIONS
37	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	84
38	Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. <i>Neurology</i> , 2018, 90, e96-e102.	1.5	82
39	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. <i>Neurology</i> , 2021, 97, e1097-e1109.	1.5	77
40	Primary leptomeningeal lymphoma. <i>Neurology</i> , 2013, 81, 1690-1696.	1.5	70
41	Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. <i>Journal of Neuroimmunology</i> , 2018, 323, 62-72.	1.1	68
42	Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 897-907.	0.9	66
43	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. <i>Multiple Sclerosis Journal</i> , 2021, 27, 303-308.	1.4	64
44	Optic neuritis in the era of biomarkers. <i>Survey of Ophthalmology</i> , 2020, 65, 12-17.	1.7	60
45	Progressive solitary sclerosis. <i>Neurology</i> , 2016, 87, 1713-1719.	1.5	59
46	Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1285-1297.	1.6	58
47	Optical coherence tomography is highly sensitive in detecting prior optic neuritis. <i>Neurology</i> , 2019, 92, e527-e535.	1.5	56
48	Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients. <i>JAMA Neurology</i> , 2020, 77, 257.	4.5	56
49	Elsberg syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e355.	3.1	55
50	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e343.	3.1	55
51	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 384-390.	0.9	55
52	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 488-490.	0.9	54
53	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 218-225.	0.9	53
54	LGI1 and CASPR2 neurological autoimmunity in children. <i>Annals of Neurology</i> , 2018, 84, 473-480.	2.8	53

#	ARTICLE	IF	CITATIONS
55	Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin Gâ€™Associated Disorder. JAMA Neurology, 2020, 77, 1575.	4.5	52
56	Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. American Journal of Ophthalmology, 2020, 220, 110-114.	1.7	48
57	LGI1 antibody encephalitis: acute treatment comparisons and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 309-315.	0.9	48
58	Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Medicine, 2015, 16, 1502-1510.	0.8	45
59	Unique Gadolinium Enhancement Pattern in Spinal Dural Arteriovenous Fistulas. JAMA Neurology, 2018, 75, 1542.	4.5	44
60	Paraneoplastic Myelopathy. Neurologic Clinics, 2013, 31, 307-318.	0.8	43
61	Neuromyelitis Optica Spectrum Disorders. Current Neurology and Neuroscience Reports, 2014, 14, 483.	2.0	42
62	Autoimmune myelopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 327-351.	1.0	42
63	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. Clinical Chemistry, 2020, 66, 1496-1509.	1.5	41
64	Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Frontiers in Neurology, 2021, 12, 673339.	1.1	40
65	Neuromyelitis Optica Spectrum Disorder and Other Nonâ€™Multiple Sclerosis Central Nervous System Inflammatory Diseases. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 815-844.	0.4	40
66	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibodyâ€™Associated Disease. JAMA Neurology, 2022, 79, 518.	4.5	39
67	Autoimmune Encephalopathy. Seminars in Neurology, 2011, 31, 144-157.	0.5	38
68	Paraneoplastic lower motor neuronopathy associated with Hodgkin lymphoma. Muscle and Nerve, 2012, 46, 823-827.	1.0	38
69	Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2017, 74, 359.	4.5	38
70	[18F]-Fluorodeoxyglucoseâ€™Positron Emission Tomography in Patients With Active Myelopathy. Mayo Clinic Proceedings, 2013, 88, 1204-1212.	1.4	37
71	Imaging Review of Paraneoplastic Neurologic Syndromes. American Journal of Neuroradiology, 2020, 41, 2176-2187.	1.2	37
72	Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibodyâ€™Positive Meningoencephalitis. Journal of Neuro-Ophthalmology, 2018, 38, 276-281.	0.4	36

#	ARTICLE	IF	CITATIONS
73	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103525.	0.9	36
74	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1808-1817.	1.4	35
75	Elevated <scp>LGI</scp>1â€lgG <scp>CSF</scp> index predicts worse neurological outcome. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 646-650.	1.7	35
76	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101487.	0.9	35
77	A practical approach to the diagnosis of spinal cord lesions. <i>Practical Neurology</i> , 2018, 18, 187-200.	0.5	34
78	Dominant Frontotemporal Dementia Mutations in 140 Cases of Primary Progressive Aphasia and Speech Apraxia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 281-286.	0.7	32
79	Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. <i>Brain Communications</i> , 2021, 3, fcaa233.	1.5	31
80	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgGâ€associated disorders (MOGAD)?. <i>Neurology</i> , 2020, 94, 85-88.	1.5	30
81	MOG-IgG1 and co-existence of neuronal autoantibodies. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1175-1186.	1.4	29
82	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	29
83	Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. <i>Mayo Clinic Proceedings</i> , 2022, 97, 547-559.	1.4	29
84	Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	29
85	Spinal cord infarction: Clinical and imaging insights from the periprocedural setting. <i>Journal of the Neurological Sciences</i> , 2018, 388, 162-167.	0.3	28
86	Neurochondrin neurological autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	28
87	Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis. <i>Neurology</i> , 2021, 97, e1141-e1149.	1.5	27
88	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. <i>Neurology</i> , 2019, 93, e414-e420.	1.5	26
89	Paraneoplastic Myeloneuropathies. <i>Neurology</i> , 2021, 96, e632-e639.	1.5	26
90	Collapsin Response-Mediator Protein 5â€Associated Retinitis, Vitritis, and Optic Disc Edema. <i>Ophthalmology</i> , 2020, 127, 221-229.	2.5	25

#	ARTICLE	IF	CITATIONS
91	Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 630-635.	1.4	25
92	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. <i>Neurology</i> , 2021, 97, e1351-e1358.	1.5	25
93	NEDA treatment target? No evident disease activity as an actionable outcome in practice. <i>Journal of the Neurological Sciences</i> , 2017, 383, 31-34.	0.3	24
94	Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1299-1304.	1.4	24
95	Posttransplant autoimmune encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e497.	3.1	24
96	Optic chiasm involvement in AQP-4 antibodyâ€“positive NMO and MOG antibodyâ€“associated disorder. <i>Multiple Sclerosis Journal</i> , 2022, 28, 149-153.	1.4	24
97	Secondary intramedullary spinal cord non-Hodgkinâ€™s lymphoma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 575-580.	1.4	23
98	Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-320243.	0.9	23
99	Diagnostic and Therapeutic Approach to Autoimmune Neurologic Disorders. <i>Seminars in Neurology</i> , 2018, 38, 392-402.	0.5	22
100	Unilateral motor progression in MS. <i>Neurology</i> , 2019, 93, e628-e634.	1.5	22
101	Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. <i>Neuro-Ophthalmology</i> , 2020, 44, 1-4.	0.4	22
102	Unilateral Leptomeningeal Enhancement in Myelin Oligodendrocyte Glycoprotein Immunoglobulin Gâ€“Associated Disease. <i>JAMA Neurology</i> , 2020, 77, 648.	4.5	22
103	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. <i>Neurology: Clinical Practice</i> , 2015, 5, 175-177.	0.8	21
104	Autoimmune and Paraneoplastic Myelopathies. <i>Seminars in Neurology</i> , 2018, 38, 278-289.	0.5	21
105	Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions. <i>Neurology: Clinical Practice</i> , 2021, 11, e601-e611.	0.8	21
106	Striking basal ganglia imaging abnormalities in LGI1 ab faciobrachial dystonic seizures. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e336.	3.1	20
107	Breast cancer-related paraneoplastic neurologic disease. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 771-778.	1.1	20
108	Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102638.	0.9	20

#	ARTICLE	IF	CITATIONS
109	A path to understanding autoimmune GFAP astrocytopathy. <i>European Journal of Neurology</i> , 2018, 25, 421-422.	1.7	19
110	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOMentum Study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103352.	0.9	19
111	Diagnosis and management of spinal cord emergencies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2017, 140, 319-335.	1.0	18
112	Trident sign trumps Aquaporin-4-IgG ELISA in diagnostic value in a case of longitudinally extensive transverse myelitis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 7-8.	0.9	18
113	Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1445-1452.	1.4	18
114	Clinical Utility of Antiretinal Antibody Testing. <i>JAMA Ophthalmology</i> , 2021, 139, 658.	1.4	18
115	Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. <i>JAMA Neurology</i> , 2018, 75, 892.	4.5	17
116	<scp>Anti-Neuronal</scp> Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1. <i>Annals of Neurology</i> , 2022, 91, 670-675.	2.8	17
117	Autoimmune dementia and encephalopathy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 247-267.	1.0	16
118	Spontaneous posterior spinal artery infarction. <i>Neurology</i> , 2018, 91, 414-417.	1.5	16
119	Diagnosis and Management of Autoimmune Dementia. <i>Current Treatment Options in Neurology</i> , 2019, 21, 11.	0.7	16
120	Myelitis and Other Autoimmune Myelopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2021, 27, 62-92.	0.4	16
121	<scp>Multiple Sclerosis</scp> Is Rare in Epstein-Barr Virus-Seronegative Children with <scp>Central Nervous System</scp> Inflammatory Demyelination. <i>Annals of Neurology</i> , 2021, 89, 1234-1239.	2.8	16
122	High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103253.	0.9	16
123	Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 425-439.	1.7	16
124	Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. <i>Frontiers in Neurology</i> , 2022, 13, 866824.	1.1	16
125	Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis. <i>Journal of Neurology</i> , 2020, 267, 3337-3342.	1.8	15
126	FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis With Seizures (FLAMES): Is immunotherapy always needed to put out the fire?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102283.	0.9	15

#	ARTICLE	IF	CITATIONS
127	Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199890.	1.5	15
128	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-associated Disorders. JAMA Neurology, 2020, 77, 1572.	4.5	14
129	CASPR2-associated autoimmune seizures. Epilepsia, 2022, 63, 709-722.	2.6	14
130	Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics, 2022, 19, 808-822.	2.1	14
131	Adult-onset autosomal dominant leukodystrophy presenting with REM sleep behavior disorder. Neurology, 2013, 80, 118-120.	1.5	13
132	Dementia in MS complicated by coexistent Alzheimer disease. Neurology: Clinical Practice, 2014, 4, 226-230.	0.8	13
133	A multi-center case series of sarcoid optic neuropathy. Journal of the Neurological Sciences, 2021, 420, 117282.	0.3	13
134	Amiodarone-associated neuromyopathy: a report of four cases. European Journal of Neurology, 2012, 19, e50-1.	1.7	12
135	Clinical and Radiologic Features, Pathology, and Treatment of Baló's Concentric Sclerosis. Neurology, 2021, 97, e414-e422.	1.5	12
136	Amyloid- β -related angiitis presenting as a uveomeningeal syndrome. Neurology, 2013, 81, 1796-1798.	1.5	11
137	Teaching Neuro  : "Pancake-like" gadolinium enhancement suggests compressive myelopathy due to spondylosis. Neurology, 2013, 80, e229.	1.5	11
138	Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. Neurocase, 2016, 22, 55-59.	0.2	11
139	Utility of extension views in spondylotic myelopathy mimicking transverse myelitis. Multiple Sclerosis and Related Disorders, 2017, 11, 62-64.	0.9	11
140	Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. European Journal of Neurology, 2022, 29, 782-789.	1.7	11
141	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110526.	0.5	11
142	Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder. Neurology: Clinical Practice, 2013, 3, 448-451.	0.8	10
143	B-cell-targeted therapies in relapsing forms of MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e405.	3.1	10
144	Foot and ankle surgery "The Achilles heel of medical students and doctors. Foot, 2011, 21, 109-113.	0.4	9

#	ARTICLE	IF	CITATIONS
145	Anterior spinal artery infarction causing man-in-the-barrel syndrome. <i>Neurology: Clinical Practice</i> , 2014, 4, 268-269.	0.8	9
146	Conjunctival biopsy to diagnose neurosarcoidosis in patients with inflammatory nervous system disease of unknown etiology. <i>Neurology: Clinical Practice</i> , 2015, 5, 216-223.	0.8	9
147	A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 115-117.	0.9	9
148	Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. <i>Stroke</i> , 2021, 52, 645-654.	1.0	9
149	Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103310.	0.9	9
150	Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease. <i>American Journal of Hematology</i> , 2022, 97, 293-302.	2.0	9
151	Autoimmune Myelopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2011, 17, 776-799.	0.4	8
152	Addition of Magnetic Resonance Imaging to Computed Tomography and Sensitivity to Blood in Pituitary Apoplexy. <i>Archives of Neurology</i> , 2011, 68, 1336.	4.9	8
153	Fulminant cerebellitis with radiological recurrence in an adult patient with Crohn's disease. <i>Journal of the Neurological Sciences</i> , 2014, 336, 247-250.	0.3	8
154	Clinical Reasoning: A 56-year-old woman with acute vertigo and diplopia. <i>Neurology</i> , 2018, 90, 748-752.	1.5	8
155	Unfavorable outcome in highly relapsing MOGAD encephalitis. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117088.	0.3	8
156	Evaluation and Management of Acute Myelopathy. <i>Seminars in Neurology</i> , 2021, 41, 511-529.	0.5	8
157	Sjögren's syndrome with trigeminal neuropathy: motor involvement. <i>Practical Neurology</i> , 2013, 13, 340-342.	0.5	7
158	Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis. <i>Journal of the Neurological Sciences</i> , 2016, 361, 204-205.	0.3	7
159	MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting. <i>Multiple Sclerosis Journal</i> , 2020, 26, 997-1000.	1.4	7
160	Expanded genetic insight and clinical experience of DNMT1-complex disorder. <i>Neurology: Genetics</i> , 2020, 6, e456.	0.9	7
161	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 667-673.	1.4	7
162	Paraneoplastic Disorders of the Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 1602-1628.	0.4	7

#	ARTICLE	IF	CITATIONS
163	Myelin oligodendrocyte glycoprotein (MOG) antibodies in a patient with glioblastoma: Red flags for false positivity. <i>Journal of Neuroimmunology</i> , 2021, 361, 577743.	1.1	7
164	Exposure to TNF inhibitors is rare at MOGAD presentation. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120044.	0.3	7
165	Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis. <i>Brain Communications</i> , 2022, 4, .	1.5	7
166	Myelitis in neuromyelitis optica spectrum disorder: The long and the short of it. <i>Multiple Sclerosis Journal</i> , 2017, 23, 360-361.	1.4	6
167	Population-based study of œno evident disease activityœin MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e495.	3.1	6
168	Spinal cord transient ischemic attack. <i>Neurology: Clinical Practice</i> , 2020, 10, 480-483.	0.8	6
169	Paraneoplastic disorders of the nervous system. <i>Journal of Neurology</i> , 2021, 268, 4899-4907.	1.8	6
170	Clinical Reasoning: A 54-year-old woman with dementia, myoclonus, and ataxia. <i>Neurology</i> , 2017, 89, e7-e12.	1.5	5
171	Teaching Video Neurolmages: Paroxysmal Dysarthria-Ataxia in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e2245-e2246.	1.5	5
172	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110487.	0.5	5
173	Investigating the Immunopathogenic Mechanisms Underlying <scp>MOGAD</scp>. <i>Annals of Neurology</i> , 2022, 91, 299-300.	2.8	5
174	IgG4œrelated (neurologic) disease: diagnostic challenges, clinical clues and expanding spectrum. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 807-809.	0.9	4
175	Clinical Reasoning: A 30-year-old man with headache and sleep disturbance. <i>Neurology</i> , 2018, 90, e1535-e1540.	1.5	4
176	Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2019, 92, 343-344.	1.5	4
177	Glial Fibrillary Acidic Protein (GFAP) Autoimmunity in the Setting of Seropositive Rheumatoid Arthritis Treated With Etanercept. <i>Neurologist</i> , 2019, 24, 152-154.	0.4	4
178	Area postrema syndrome in autoimmune GFAP astrocytopathy. <i>Multiple Sclerosis Journal</i> , 2020, 26, 255-256.	1.4	4
179	Enlarging Perivascular Spaces Following Radiation Therapy in the Brain: A Report of 2 Cases and Literature Review. <i>World Neurosurgery</i> , 2020, 138, 436-439.	0.7	4
180	Spinal arteriovenous fistula's often misdiagnosed as myelitis; can we stem the flow?. <i>Journal of the Neurological Sciences</i> , 2020, 413, 116868.	0.3	4

#	ARTICLE	IF	CITATIONS
181	Autoimmune psychosis. <i>Lancet Psychiatry</i> , 2020, 7, 122.	3.7	4
182	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. <i>Multiple Sclerosis Journal</i> , 2021, 27, 895-902.	1.4	4
183	Uncommon inflammatory/immune-related myelopathies. <i>Journal of Neuroimmunology</i> , 2021, 361, 577750.	1.1	4
184	Understanding the etiology and epidemiology of meningitis and encephalitis: now and into the future. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 20, 100380.	1.3	4
185	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt-Jakob disease and autoimmune encephalitis. <i>European Journal of Neurology</i> , 2022, 29, 2905-2912.	1.7	4
186	Clinical Reasoning: A 55-year-old man with weight loss, ataxia, and foot drop. <i>Neurology</i> , 2014, 82, e214-9.	1.5	3
187	Paroxysmal sneezing in NMOSD: Further evidence of the localization of the human sneeze center. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e303.	3.1	3
188	Dacrytic seizures: A cry for help. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e372.	3.1	3
189	Isolated recurrent myelitis in a persistent MOG positive patient. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 163-164.	0.9	3
190	Inflammatory activity following motor progression due to critical CNS demyelinating lesions. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1037-1045.	1.4	3
191	In reply "Sensitivity of [18F]-fluorodeoxyglucose Positron Emission Tomography in Patients With Active Myelopathy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 859.	1.4	2
192	Reply to "epidemiology of autoimmune versus infectious encephalitis". <i>Annals of Neurology</i> , 2018, 83, 1038-1038.	2.8	2
193	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. <i>Lancet Neurology</i> , 2018, 17, 498-499.	4.9	2
194	Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 34-35.	0.9	2
195	Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e620.	3.1	2
196	Unilateral Cortical Fluid-Attenuated Inversion Recovery "Hyperintense Lesions in Anti-Myelin Oligodendrocyte Glycoprotein Associated Encephalitis With Seizures (FLAMES): An Under-recognized Entity. <i>Pediatric Neurology</i> , 2020, 110, 99-100.	1.0	2
197	MRI with neck extension to diagnose cervical spondylotic myelopathy. <i>Practical Neurology</i> , 2022, 22, 162-163.	0.5	2
198	Teaching case in MS differential diagnosis: A Longstanding diagnosis of MS with severe disability. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103540.	0.9	2

#	ARTICLE	IF	CITATIONS
199	Reader response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2019, 93, 722-723.	1.5	1
200	Holmes tremor with peri-rolandic demyelinating lesions. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000011235.	1.5	1
201	COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? â€“ Commentary. <i>Multiple Sclerosis Journal</i> , 2021, 27, 976-977.	1.4	1
202	Reader Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies. <i>Neurology</i> , 2021, 96, 186-188.	1.5	1
203	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732110521.	0.5	1
204	Paraneoplastic myelopathy with amphiphysin autoantibodies and lobular breast carcinoma in situ. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120086.	0.3	1
205	The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1710-1718.	1.4	1
206	Clinical commentary on â€“Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new casesâ€™, by Wang et al.. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1954-1955.	1.4	0
207	Author response: Clinical Reasoning: A 56-year-old woman with acute vertigo and diplopia. <i>Neurology</i> , 2019, 92, 249-249.	1.5	0
208	003â€“...Autoimmune encephalitis antibody biomarkers: frequency, age and sex associations. , 2021, , .		0
209	Harry Lee Parker. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 701-719.	1.2	0
210	Inflammatory leukoencephalopathy mimicking hereditary disease. <i>Neuroimmunology Reports</i> , 2022, 2, 100092.	0.2	0